Home/Autifony Therapeutics/Hannah Selin, FCCA

HS

Hannah Selin, FCCA

Chief Financial Officer

Autifony Therapeutics

Therapeutic Areas

Rare CNS Disorders Epilepsy Neurodevelopmental Disorders Hearing Loss Schizophrenia

Autifony Therapeutics Pipeline

Drug	Indication	Phase
AUT00206	Fragile X Syndrome	Clinical
AUT00201	Rare Myoclonic Epilepsy Syndromes	Clinical
Preclinical Kv3 Modulators	Schizophrenia	Preclinical
Early-stage Ion Channel Programs	Neurodegenerative / Hyperexcitability Disorders	Discovery

Leadership Team at Autifony Therapeutics

Charles H. Large, PhD

Founder and Chief Executive Officer

Daniel Umbricht, MD

Chief Medical Officer

Barbara Domayne-Hayman, DPhil

Chief Business Officer

Martin Gunthorpe, PhD

Chief Technology Officer

View full Autifony Therapeutics profile